Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31589356 | 1.00 | TNF (0.57) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1536597 | 0.89 | TNF (0.48) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL13409741 | 0.89 | TNF (0.49) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1205625 | 0.88 | TNF (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL6827179 | 0.87 | PDE3B (0.51) | TNFPDE10APDE3BPDE3AACHE | |
| SCHEMBL25370499 | 0.86 | SMN1; SMN2 (0.49) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL628689 | 0.86 | APAF1 (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL6768992 | 0.86 | TNF (0.46) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL1536600 | 0.86 | TRPA1 (0.52) | TNFPDE10APDE3BPDE3ACYP3A4 | |
| SCHEMBL6326557 | 0.86 | APAF1 (0.47) | TNFPDE10APDE3BPDE3ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100534986-C | Method for preparing derivative of 1,4 - dichloro isoquinoline category | UNIV ZHEJIANG POLYTECHNIC (CN) | 2009-09-02 | — | — | CN | claimed |
| CN-101092395-A | Method for preparing derivative of 1,4 - dichloro isoquinoline category | UNIV ZHEJIANG POLYTECHNIC (CN) | 2007-12-26 | — | — | CN | claimed |
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | GLIAPHARM SA (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4598533-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | Gliapharm SA (CH) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025016273-A1 | ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USES OF ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION | 拜西欧斯（北京）生物技术有限公司 | 2025-01-23 | — | — | WO | disclosed |
| WO-2024074436-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | GLIAPHARM SA (CH) | 2024-04-11 | — | — | WO | disclosed |
| US-20230102415-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | GLIAPHARM SA (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2021136763-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | GLIAPHARM SA (CH) | 2021-07-08 | — | — | WO | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| EP-0370381-B1 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-05-10 | — | — | EP | disclosed |
| EP-0393926-B1 | 1-Aminoisoquinoline derivatives | SMITHKLINE BEECHAM INTERCREDIT (NL) | 1994-09-21 | — | — | EP | disclosed |
| US-5200417-A | Administering to inhibait gastric acid secretion in mammals | SMITHKLINE BEECHAM INTERCREDIT B.V. (GB) | 1993-04-06 | — | — | US | disclosed |
| US-4988698-A | Cardiovascular disorders, hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0393926-A1 | 1-Aminoisoquinoline derivatives | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1990-10-24 | — | — | EP | disclosed |
| CN-1042905-A | The preparation method of 2 (1H) quinolinone compounds and medicinal compositions thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-06-13 | — | — | CN | disclosed |
| EP-0370381-A2 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-3966936-A | MUSCLE RELAXANTS | PFIZER INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3932412-A | HYPOTENSIVE, ANTISHOCK, ANTIANGINA | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | TNF 3963/4885PDE10A 2450/4885PDE3B 750/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | TNF 3963/4885PDE10A 2450/4885PDE3B 750/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | TNF 3963/4885PDE10A 2450/4885PDE3B 750/4885 |
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | LDHA, PC, LDHB | TNF 2981/4885PDE10A 1997/4885PDE3B 1656/4885 |
| US-20230102415-A1 | ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME | SLC2A1, SLC2A2, SLC2A3 | TNF 4841/4885PDE10A 2621/4885PDE3B 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.